Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8241-8252

  Ge, Jinying ^a   Wang, Xijun ^a   Tao, Lihong ^a   Wen, Zhiyuan ^a   Fen, Na ^b   Yang, Songtao ^b   Xia, Xianzhu ^b   Yang, Chinglai ^c   Chen, Hualan ^a   Bu, Zhigao ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VIRUS GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CAT; CELL SPREADING; CHEMOSENSITIVITY; CONTROLLED STUDY; DOG; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; LOW DRUG DOSE; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; VIROGENESIS; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALIA; AVES; CANIS FAMILIARIS; MAMMALIA; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; RABIES VIRUS;

EID: 79961198209     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00519-11     Document Type: Article

References (66)

1. Alexander, D. J.Anonymous. 2009. Human vaccinia infection after contact with a raccoon rabies vaccine bait-Pennsylvania, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1204-1207.
2. Alexander, D. J. 1989. Newcastle disease. American Association for Avian Pathologists, Kennett Square, PA.
3. Alexander, D. J. 1997. Newcastle disease and other avian paramyxoviridae infections. Iowa State University Press, Ames, IA.
4. Blach-Olszewska, Z. 1970. Interferon induction by Newcastle disease virus in mice. Arch. Immunol. Ther. Exp. (Warsz.). 18:418-441.
5. Brehm, G., and H. Kirchner. 1986. Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. J. Interferon Res. 6:21-28.
6. Buchholz, U. J., et al. 2005. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J. Virol. 79:6588-6597.
7. Bukreyev, A., and P. L. Collins. 2008. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 10:46-55.
8. Bukreyev, A., et al. 2005. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79:13275-13284.
9. Bukreyev, A., et al. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81:6379-6388.
10. Bukreyev, A., M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins. 2006. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 80:10293-10306.
11. Bukreyev, A., et al. 2006. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80:2267-2279.
12. Chen, W., et al. 2010. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep. Vaccine 28:4742-4750.
13. Dietzschold, B., M. Schnell, and H. Koprowski. 2005. Pathogenesis of rabies. Curr. Top. Microbiol. Immunol. 292:45-56.
14. Dietzschold, B., et al. 1985. Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J. Virol. 56:12-18.
15. DiNapoli, J. M., et al. 2007. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. U. S. A. 104:9788-9793.
16. DiNapoli, J. M., et al. 2010. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84:1489-1503.
17. DiNapoli, J. M., et al. 2009. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27:1530-1539.
18. DiNapoli, J. M., et al. 2007. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81:11560-11568.
19. Faber, M., et al. 2009. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. U. S. A. 106:11300-11305.
20. Faber, M., et al. 2004. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc. Natl. Acad. Sci. U. S. A. 101:16328-16332.
21. Flamand, A., H. Raux, Y. Gaudin, and R. W. Ruigrok. 1993. Mechanisms of rabies virus neutralization. Virology 194:302-313.
22. Fu, Z. F. 1997. Rabies and rabies research: past, present and future. Vaccine 15:S20-S24.
23. Gao, W., et al. 2006. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80:1959-1964.
24. Gaudin, Y., R. W. Ruigrok, M. Knossow, and A. Flamand. 1993. Low-pH conformational changes of rabies virus glycoprotein and their role in membrane fusion. J. Virol. 67:1365-1372.
25. Ge, J., et al. 2007. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 81:150-158.
26. Ge, J., et al. 2010. Generation and evaluation of a Newcastle disease virusbased H9 avian influenza live vaccine. Avian Dis. 54:294-296.
27. Hanlon, C. A., et al. 1998. First North American field release of a vacciniarabies glycoprotein recombinant virus. J. Wildl. Dis. 34:228-239.
28. Huang, Z., S. Elankumaran, A. S. Yunus, and S. K. Samal. 2004. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J. Virol. 78:10054-10063.
29. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2003. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 77:8676-8685.
30. Jiao, P., et al. 2008. A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J. Virol. 82:1146-1154.
31. Kanesa-thasan, N., et al. 2000. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19:483-491.
32. Khattar, S. K., P. L. Collins, and S. K. Samal. 2010. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 28:3159-3170.
33. Knobel, D. L., et al. 2005. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 83:360-368.
34. Kortekaas, J., et al. 2010. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28:2271-2276.
35. Krempl, C., B. R. Murphy, and P. L. Collins. 2002. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J. Virol. 76:11931-11942.
36. Krishnamurthy, S., Z. Huang, and S. K. Samal. 2000. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278:168-182.
37. Lembo, T., et al. 2010. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl. Trop. Dis. 4:e626.
38. Li, Z., et al. 2006. The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. J. Virol. 80:11115-11123.
39. Lodmell, D. L., J. F. Bell, G. J. Moore, and G. H. Raymond. 1969. Comparative study of abortive and nonabortive rabies in mice. J. Infect. Dis. 119: 569-580.
40. Lodmell, D. L., L. C. Ewalt, M. J. Parnell, C. E. Rupprecht, and C. A. Hanlon. 2006. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine 24:412-416.
41. Martinez-Sobrido, L., et al. 2006. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80:1130-1139.
42. McCoy, K., et al. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
43. Mehta, S. R., et al. 2009. Early versus delayed invasive intervention in acute coronary syndromes. N. Engl. J. Med. 360:2165-2175.
44. Nakaya, T., et al. 2001. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75:11868-11873.
45. Nakaya, Y., et al. 2004. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J. Virol. 78:9366-9375.
46. Neumann, G., M. A. Whitt, and Y. Kawaoka. 2002. A decade after the generation of a negative-sense RNA virus from cloned cDNA-what have we learned? J. Gen. Virol. 83:2635-2662.
47. Osinubi, M. O., et al. 2009. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine 27:7214-7218.
48. Panda, A., Z. Huang, S. Elankumaran, D. D. Rockemann, and S. K. Samal. 2004. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb. Pathog. 36:1-10.
49. Park, M. S., A. Garcia-Sastre, J. F. Cros, C. F. Basler, and P. Palese. 2003. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 77:9522-9532.
50. Park, M. S., J. Steel, A. Garcia-Sastre, D. Swayne, and P. Palese. 2006. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. U. S. A. 103:8203-8208.
51. Peeters, B. P., O. S. de Leeuw, G. Koch, and A. L. Gielkens. 1999. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73:5001-5009.
52. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
53. Reynard, O., et al. 2009. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J. Virol. 83:9596-9601.
54. Sharpe, S., et al. 2001. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virusAnkara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82:2215-2223.
55. Smith, J. S., P. A. Yager, and G. M. Baer. 1973. A rapid reproducible test for determining rabies neutralizing antibody. Bull. World Health Organ. 48:535-541.
56. Tao, L., et al. 2010. Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation. J. Virol. 84:8926-8936.
57. Veits, J., et al. 2006. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. U. S. A. 103:8197-8202.
58. Wandeler, A. I., S. Capt, A. Kappeler, and R. Hauser. 1988. Oral immunization of wildlife against rabies: concept and first field experiments. Rev. Infect. Dis. 10(Suppl. 4):S649-S653.
59. Weingartl, H. M., et al. 2006. Recombinant Nipah virus vaccines protect pigs against challenge. J. Virol. 80:7929-7938.
60. Wilde, H., et al. 2005. Rabies control in South and Southeast Asia. Vaccine 23:2284-2289.
61. World Health Organization. 2005. WHO expert consultation on rabies. First report. WHO Technical Report Series 931. World Health Organization, Geneva, Switzerland.
62. Wu, X., and C. E. Rupprecht. 2008. Glycoprotein gene relocation in rabies virus. Virus Res. 131:95-99.
63. Wyatt, L. S., B. Moss, and S. Rozenblatt. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.
64. Yang, L., et al. 2008. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377:255-264.
65. Yang, Z. Y., et al. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77:799-803.
66. Zhao, L., et al. 2010. Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. J. Virol. 84:9642-9648.